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ABSTRACT
Aim: Patent ductus arteriosus (PDA) is treated with ibuprofen and it is known that the clearance
of ibuprofen increases with postnatal age. We aimed to study whether postnatal age-adjusted
ibuprofen dosages improve the effectiveness of treatment compared to standard ibuprofen dos-
ages after the first days of life.
Methods: A historical cohort of 207 preterm neonates treated with standard ibuprofen dosages
(Group A; 2011–2015) was compared to a prospective cohort of 66 preterm neonates treated
with postnatal age-adjusted ibuprofen dosages (Group B; 2015–2016).
Results: Both groups had comparable background characteristics. Treatment was started after
median 6 (25–75th percentile: 4–11) and 5 (25–75th percentile: 4–11) days and effectiveness
was 33.2 and 44.7% (p¼ .17) in groups A and B, respectively. No hemodynamically significant
PDA was found in 23/49 (46.9%) of the patients born before 28 weeks after adjusted ibuprofen
dosages compared to 48/162 (29.6%) after standard ibuprofen dosages (p¼ .04). There were sig-
nificantly more reversible side effects with the postnatal age-adjusted ibuprofen dos-
ages (p¼ .04).
Conclusions: There seems to be a trend to higher effectiveness with the adjusted ibuprofen
dosages in preterm neonates before 28 weeks, but it is associated with more reversible
side effects.
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While the ductus arteriosus normally closes spontan-
eously after term birth, it often remains open in pre-
term neonates. This condition, known as patent
ductus arteriosus (PDA), may result in hemodynamic
changes related to a left-to-right shunt, such as pul-
monary fluid overload and decreased systemic circula-
tion [1]. This has been associated with prolonged
ventilation, chronic lung disease, and necrotizing
enterocolitis (NEC). PDA can be treated pharmaco-
logically or by surgical ligation. The best strategy to
manage PDA pharmacologically is still being debated
internationally [2].
Historically, the NSAID indomethacin was the
pharmacological treatment of choice [3]. In 1996, how-
ever, Varvarigou et al. showed that ibuprofen was
effective to close the ductus arteriosus [4], especially
when given during the first three postnatal days. Since
then, the effectiveness of ibuprofen for PDA in pre-
term neonates has been further studied [5,6] and the
drug has been registered for intravenous application
at a dose of 10, 5, and 5mg/kg body weight once
daily for three consecutive days. Meanwhile, these
dosages have been widely implemented as standard
of care in the neonatal intensive care unit (NICU).
Many trials compared ibuprofen with indomethacin
[6,7]. Ibuprofen seems to carry fewer side effects than
does indomethacin and is, therefore, often considered
to be the first drug in PDA treatment [6].
The optimal timing and dosage of ibuprofen remain
unclear. Relatively late treatment with ibuprofen might
be effective [8,9]. Awaiting spontaneous closure during
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the first days of life could prevent overtreatment and
potential side effects. In 2008, Hirt et al. showed that
ibuprofen clearance importantly increases with postna-
tal age (PNA) and proposed to increase ibuprofen dos-
age accordingly after the first days of life [10].
Effectiveness of the increased dosages still needs
evaluation in clinical practice.
In this cohort study, we studied the use of ibupro-
fen dosages that were adjusted to postnatal age. The
effectiveness and side effects were compared to the
registered ibuprofen dosages.
Materials and methods
All preterm neonates admitted to the level III NICU of
the Erasmus UMC-Sophia, Rotterdam, the Netherlands,
from September 2011 to November 2016 and who
received ibuprofen for PDA treatment were eligible in
this before–after cohort study. Neonates with a gesta-
tional age above 30 weeks were excluded. Neonates
who received paracetamol as a first PDA treatment or
ibuprofen dosages that differed from the protocol
were excluded. In June 2015, postnatal age-adjusted
ibuprofen dosing was introduced as standard of care.
Prospectively collected data before June 2015 were
analyzed retrospectively. From June 2015 to
November 2016 data were prospectively collected.
The primary outcome was the rate of no hemo-
dynamically significant ductus arteriosus (no-hsPDA)
after ibuprofen therapy. No-hsPDA is described as a
ductus arteriosus smaller than 1.5mm and left atrium
(LA)/aorta (Ao) ratio < 1.4. Secondary outcomes
included subgroup analysis of neonates under 26 and
28 weeks of gestation, reported side effects (oliguria,
intraventricular hemorrhage (IVH), gastrointestinal
bleeding or perforation, and NEC).
Persistent ductus arteriosus
According to our treatment policy, neonates with a ges-
tational age under 26 weeks were routinely screened for
hsPDA at the fourth postnatal day. Neonates born
between 26 and 28 weeks, echocardiography was indi-
cated at the fourth postnatal day (from June 2015) or
within the first week of life (before June 2015). Neonates
born after 28 weeks echocardiography was performed
based on clinical signs related to hsPDA. If ibuprofen
was contraindicated no echocardiography was made
because of absent clinical consequences. After three ibu-
profen doses, a control echocardiography was per-
formed within 24h. Echocardiographic examinations
were performed by experienced cardiac sonographers or
pediatric cardiologists using a Vivid-S6 (GE Health Care,
Chicago, IL) two-dimensional color Doppler echocardio-
graphic system equipped with a 10MHz transducer. For
this study, all echocardiographic images were reeval-
uated afterward by one and the same trained physician
(JdeK), who was blinded for patients characteristics and
ibuprofen data at the time of evaluation.
Treatment policy was to start ibuprofen in patients
with a hsPDA (ductal diameter >2.0mm, PDA/LPA
diameter >0.8, and/or LA/Ao ratio >1.6).
Relative contraindications for start or continuation of
ibuprofen treatment were active (intracerebral) hemor-
rhage, thrombocytopenia (< 100 109/l) or other
known clotting disorders, sepsis (positive blood culture),
suspected or confirmed NEC, intestinal perforation, liver
or kidney function disorders (oliguria < 1.0ml/kg/h or
serum creatinine >110 mmol/l), or severe hyperbilirubi-
nemia. In case of temporary contraindications, ibuprofen
could be started or continued later, albeit at the discre-
tion of the attending physician.
Registered dosing protocol (group A)
From September 2011 to June 2015, the registered
intravenous ibuprofen dosing protocol was used
(10–5–5mg/kg in three consecutive days). If hsPDA
persisted, a second similar course of ibuprofen was
administered. If then ductal patency persisted, a third
ibuprofen course or a course of paracetamol could be
considered [11].
Postnatal age-adjusted dosing (group B)
From June 2015 to November 2016, the dose of ibupro-
fen per kg bodyweight as suggested by Hirt et al. [10]
was used as starting dose. Maintenance doses were
adapted by the suggested ongoing increase of ibuprofen
clearance during treatment. Hirt et al. used different
loading and maintenance dosages according to the post-
natal age at start of treatment, being 10–5–5, 14–7–7,
and 18–9–9mg/kg for neonates younger than 70h,
between 70 and 108h and neonates between 108 and
180h, respectively [10]. If treatment was started after
192h, the dosages were increased to 20–10–10mg/kg.
As Hirt et al. did not increase the ibuprofen maintenance
dose during treatment, our maintenance doses were
increased according to the postnatal age during treat-
ment. This was done because of the expected ongoing
increase of ibuprofen clearance during treatment. This
would lead to for instance a loading dosage of 14mg/kg
and a maintenance dosage of 9–9mg/kg. Ibuprofen
could be continued for maximally nine consecutive days.
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If enteral feeding was well tolerated gastroenteral admin-
istration of ibuprofen was considered at a dosage similar
to the intravenous dosage.
Data analyses
SPSS version 21 (IBM SPSS, Chicago, IL) was used to
analyze the data. We used an intention to treat ana-
lysis and per-protocol analyses to compare the old
versus new protocol and to compare the traditional
dosing with the postnatal age-adjusted dosing
respectively. Continuous data are presented as median
(percentiles) with ranges. Differences between the
groups were determined by t-test and Mann–Whitney
U test for parametric and nonparametric continuous
data, and a chi-square or Fisher’s exact test for cat-
egorical data. The postnatal age-adjusted dosages
were considered to be as effective as the registered
standard regimen if the closure rate is at least the
same or higher with a p value of < 0.05.
Sample size
A power analysis for the second part of the study was
performed. We considered that an absolute increase in
becoming a no-hsPDA rate of at least 20% (increase in
rate from 25% to at least 45%) would be of clinical
significance. We calculated that a sample size of 183
patients in group A and 61 patients in group B would
be necessary to determine a statistically increase of
20% in closure rate in group B at a two-sided alpha
level of 5% and with a power of 80%.
Ethical approval
Ibuprofen treatment was considered part of our rou-
tine treatment protocol for hsPDA treatment. This
observational study was submitted to the institutional
medical ethical review board, which waived the need
for approval according to the Dutch law (METRIC-
2016-126) because ibuprofen dosages and echocardi-
ography were implemented as standard of care. No
additional echocardiography, next to those performed
for routine clinical practice was permitted.
Results
A total of 314 neonates were eligible for inclusion.
Eventually, 273 were included for data analysis in the
two groups: group A (N¼ 207) treated before and
group B (N¼ 66) treated after protocol change (see
flowchart, Figure 1). The background characteristics
between the two cohorts of patients were comparable
Figure 1. Flowchart. Intention to treat analysis compared group A with group B. Per protocol analysis was compared with .
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(Table 1). Ibuprofen was started at a median postnatal
age of 6 (25th–75th percentile 4–11) days and 5
(25th–75th percentile 4–11) days (p¼ 0.99), respect-
ively, in group A and group B. In group A, 195
patients received the registered ibuprofen dosage and
twelve were treated with the postnatal age-adjusted
dosage. In group B six patients received the registered
ibuprofen dosage and 60 the new postnatal age-
adjusted dosage.
Primary outcome
No-hsPDA after treatment was found in 61/184
(33.2%) of patients in group A and in 21/47 (44.7%) in
group B (intention-to-treat analysis p¼ .17; see Figure
2). Echocardiography after treatment however, had
not been performed and patients were lost to follow-
up in 23 (11.1%) and 19 (28.8%) patients in group A
and B, respectively (p< .01). No echocardiography was
performed because patients deceased (N¼ 13), had
contra-indications for further treatment (N¼ 20) or
echocardiography was not relevant according to clin-
ician (N¼ 9).
Comparison of different dosage regimen showed
that 58/179 (32.4%) of all the patients treated with
standard ibuprofen dosage had no-hsPDA compared
with 24/52 (46.2%) of the patients treated with post-
natal age-adjusted dosages (per-protocol analyses
p¼ .07; see Figure 2).
Secondary outcome
Because closure of the ductus arteriosus becomes less
problematic with increasing gestational age subanalyses
were performed a subgroup analysis in neonates born
below 26 and 28 weeks of gestation. The PDA became
no-hsPDA in 23/49 (46.9%) of the patients born before
28 weeks receiving the adjusted ibuprofen dosages
compared to 48/162 (29.6%) if registered ibuprofen
dosages were given (p¼ .04). For newborns born before
26 weeks of gestation, the ductus became no-hsPDA in
11/25 (44%) versus 25/93 (26.9%) of patients receiving
the postnatally adjusted ibuprofen dosage and the reg-
istered dosages, respectively (p¼ .14).
In 68 of the 207 patients in group A (32.9%) side
effects were detected. These side effects were mainly
Table 1. Background characteristics of the included patients for group A and B.
Group A (2011–2015) Group B (2015–2016) p Value
Total patients admitted GA < 36 weeks 1691 555
Patients (%) included 207 (12.2%) 66 (11.9%)
Male/female (%) 108/99 (52.2/47.8) 44/22 (66.7/33.3) .05a
Median (Q1:Q3) Range Median (Q1:Q3) Range
Gestational age (weeksdays) 26 (25:27) 235294 261 (252: 266) 24–293 .96b
Birth weight (grams) 810 (700:950) 365–1550 825 (667:925) 495–1270 .98b
Apgar score at 1min (N¼ 203; N¼ 66) 5 (3:6) 0–10 5 (4:7) 1–9 .15b
Apgar score at 5min (N¼ 203; N¼ 66) 7 (6:8) 2–10 8 (6.8:8) 3–10 .12b
Postnatal age start ibuprofen (days) 6 (4:11) 2–28 5 (4:11) 3–33 .99b
BPD
Moderate 3 (1.6%) 2 (3.0%) .61a
Severe 34 (18.4%) 13 (19.7%) .86a
Mortality 46 (22.2%) 18 (27.3%) .41a
GA: gestational age; BPD: bronchopulmonary dysplasia
aFisher exact test.
bMann–Whitney U tests.
Figure 2. Results of intention to treat analysis after treatment in both groups (left panel) and of per protocol analysis after treat-
ment with standard dosages and postnatal age-adjusted dosages (right panel).
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gastrointestinal dysfunction (20%), NEC (7.8%), onset
or worsening of IVH (4.4%), gastrointestinal perforation
(2%), and oliguria (1%). Side effects (N¼ 27) occurred
in 22 of the 66 patients in group B (33.3%), including
onset or worsening of IVH (32%), gastrointestinal dys-
function (27%), NEC (18%), oliguria (14%), and gastro-
intestinal bleeding or perforation (9%). Only oliguria
(p¼ .04) and gastrointestinal dysfunction (p¼ .04)
were significantly higher in the patients who were
treated with postnatally adjusted ibuprofen dosages.
Discussion
To the best of our knowledge, this is the first pro-
spective evaluation ibuprofen treatment with dosages
adjusted to postnatal maturation of ibuprofen clear-
ance in comparison to the registered ibuprofen dos-
ages. We found that if ibuprofen treatment was
started at a median postnatal age of 6 d less than
40% of the PDA became insignificant, even with
adjusted dosages for postnatal age.
Currently there is no consensus on the best PDA
treatment strategy. Surgical ligation seems less prefer-
able and has been related to impaired neurological
outcome [12,13]. PDA in preterm neonates might also
reflect a physiological cardiopulmonary state that does
not at all benefit from pharmacological or surgical
treatment [14]. A conservative strategy might there-
fore still be considered [15]. Results from randomized
controlled trials that compare ibuprofen treatment
with no treatment at all are awaited [16].
Regarding pharmacological treatment with NSAIDs
the optimal timing (early versus late) and patient
selection (based on echocardiographic parameters, on
clinical symptoms or patient characteristics) are still
being debated [17–19].
Almost all trials on ibuprofen therapy for PDA in
preterm neonates during the last two decades
addressed the use of prophylactic [5,20] or early ibu-
profen therapy for PDA [6]. In those studies, treatment
was started almost always within 72 h after birth, often
even within 24 h. As the ductus arteriosus often might
close spontaneously during the first days of life [21], a
postponed treatment strategy would justify therapy
for only those neonates in whom spontaneous closure
in the first days fails. Our findings suggest, however,
that ibuprofen therapy is losing its effectiveness to
close the ductus if started too late, even with higher
dosing according to maturation of clearance. As ibu-
profen clearance increases significantly with postnatal
age [10], higher dosages would be needed to reach
similar ibuprofen plasma levels in older neonates. The
dosages suggested by the pharmacokinetic model of
Hirt et al. have yet to be evaluated and validated.
Increased efficacy could be reached with a double
dose of ibuprofen [22,23]. The ductus arteriosus closed
in 63% and 68% of neonates treated with registered
ibuprofen dosages compared to 86% and 92% of neo-
nates treated with double ibuprofen dosages. The
higher efficacy of ibuprofen in this trial suggests a
dose-effect relationship for ibuprofen in PDA treat-
ment. The timing of start of treatment might have
played an important role as well. In the above-men-
tioned trial, ibuprofen was started after mean postna-
tal ages of 1 and 3 d, respectively, compared to
median 6 d in our cohort [22,23].
As this study suggests, ibuprofen treatment at rela-
tively late postnatal ages should be reconsidered even
at the postnatal age-adjusted dosage. There is a trend
that treatment with postnatal age-adjusted ibuprofen
dosage leads to more no-hsPDA compared with the
registered ibuprofen dosages. An important impact of
the postnatally adjusted ibuprofen dosages is the risk
of side effects. We did not find a higher rate of severe
side effects like NEC, gastrointestinal perforation or
worsening of IVH which might have major impact.
Most of the other reported side effects seem are self-
limiting such as the significant increase in gastrointes-
tinal dysfunction and oliguria when treated with
higher ibuprofen dosages. The long-term safety,
including for instance nephrotoxic effects of these
higher ibuprofen dosages are yet unknown [24].
There is limited consensus about the echocardio-
graphic definition of a hsPDA [25]. The hemodynamic
significance is probably multifactorial. Apart from the
ductus diameter and flow through the ductus it also
depends on cardiac, pulmonary, and systemic circula-
tory effects of the ductus arteriosus that may also dif-
fer with the infant’s age, weight, and comorbidity [26].
Although surgical ligation itself is a hard outcome
measure, the indication for surgical ligation after
pharmacological treatment failed is debatable; more-
over, there are contradictory reports about the effects
of ligation on the long term outcome [12,27].
Our study is strengthened by the fact that all echo-
cardiography data were reanalyzed by one person,
thereby limiting the risk of interrater variability on the
outcome. The echocardiographic parameters to define
significance of the PDA have limitations. No details on
the systemic hypoperfusion, such as flow in the arteria
mesenterica superior or descending aortae were used
[28]. Van Laere et al. also suggest that more echocardio-
graphic parameters should be used for interpreting the
hemodynamic significance of a PDA [29]. Unfortunately,
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not all patients had been evaluated by echocardiog-
raphy after the end of treatment and loss to follow-up
was quite high. As a consequence, the exact effect of
ibuprofen therapy could not be evaluated in all patients.
Suggesting all ductus became insignificant in the non-
evaluated post treatment patients showed that the
increased ibuprofen dosages might be more slightly
effective, but are related to higher levels of side effects
(especially oliguria and gastrointestinal dysfunction).
Although a randomized placebo-controlled trial
might have been more suitable, we believe that our
cohort study clearly illustrates the limited effect of ibu-
profen after the first days of life, even at postnatal
age-adjusted dosages. It is unclear why ibuprofen was
so less effective in these premature neonates. An
important reason for this could be selection bias,
because many patients had spontaneous closure of
the duct in the first days of live and those patients
with a good clinical condition might often not be (re)-
evaluated. A case can be made for NSAIDs being more
effective in the first days of life by reinforcing the
physiological processes at work to close the duct.
In conclusion, we show low effectiveness of ibuprofen
to close the ductus arteriosus in preterm neonates if used
at older postnatal ages, even at higher dosages. There
seems a slight trend toward more effect if increased ibu-
profen dosages are used. The optimal window of oppor-
tunity for pharmacological treatment of PDA in preterm
neonates seems to be in the first days of life.
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